Christina T. Loguidice

Articles

Frontline Treatments for Metastatic RCC March Forward

September 30th 2021

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Precision Medicine Paves the Way for Advances in Hormone Receptor–Positive Breast Cancer

September 29th 2021

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Novel Combos Target Resistance Mechanisms in Advanced Hormone–Driven Breast Cancer

August 26th 2021

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape

August 5th 2021

Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge.

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments

July 22nd 2021

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

New DLBCL Treatments Are Poised to Fill an Unmet Need for Patients in Challenging Settings

May 26th 2021

During a recent OncLive Peer Exchange®, a panel of lymphoma experts discussed tafasitamab-cxix, polatuzumab vedotin-piiq, and selinexor, and how and when they use them for their patients with diffuse large B-cell lymphoma.

Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer

April 5th 2021

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Frontline ICI Therapy Gains Traction Across NSCLC Settings

March 4th 2021

Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.

Immuno-Oncology Combinations Dominate in Frontline Treatment of Advanced Clear Cell RCC

February 16th 2021

During a recent OncLive Peer Exchange®, a panel of experts in kidney cancer from the United States and France convened to discuss several important immunotherapy studies presented during the ESMO Virtual Congress 2020, as well as several others that are under way and expected to report out over the next few years.

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 5th 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Evolving Data for CLL Set Stage for Frontline Therapy

December 4th 2020

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Making Progress Against Relapsed/ Refractory DLBCL Without CAR T

November 3rd 2020

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

Targeted Therapy Options Transform AML Paradigm

October 9th 2020

An increased understanding of the biologic intricacies of acute myeloid leukemia has led to the identification of more than 100 driver mutations associated with the disease, opening the door for targeted therapies with clinically meaningful outcomes for patients who are not candidates for intensive chemo-therapy regimens.

New Options Mark Major Strides in Treating HER2+ Metastatic Breast Cancer

September 16th 2020

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

Prompt Diagnosis Is Vital in Treatment of Tenosynovial Giant Cell Tumors

September 1st 2020

During an OncLive Peer Exchange®, a panel of orthopedic experts provided a comprehensive overview of these tumors, including their epidemiology and differential diagnosis, optimal clinical workup, and the role of surgical management.

Experts Decode the Future of Biosimilars in Breast Cancer

August 25th 2020

During a recent OncLive Peer Exchange®, a panel of hematology-oncology experts discussed some of the challenges surrounding the integration of biosimilars in clinical practice using the breast cancer landscape.

PI3K Inhibitors and Oral Taxanes for Metastatic Breast Cancer: Where Do They Fit In?

August 6th 2020

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

Biosimilars Expand Patient Access to Novel Treatments

July 20th 2020

A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.

Experts Focus on 6 Life-Prolonging Treatments for mCRPC

July 9th 2020

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.